X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Newspaper Article (729) 729
Journal Article (710) 710
Publication (44) 44
Dissertation (15) 15
Patent (15) 15
Book / eBook (12) 12
Book Review (7) 7
Reference (4) 4
Magazine Article (3) 3
Book Chapter (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (303) 303
female (258) 258
oncology (251) 251
middle aged (243) 243
aged (232) 232
index medicus (209) 209
adult (208) 208
male (204) 204
school boards (138) 138
aged, 80 and over (124) 124
students (121) 121
treatment outcome (115) 115
antineoplastic combined chemotherapy protocols - therapeutic use (100) 100
neoplasms - drug therapy (97) 97
cancer (86) 86
chemotherapy (82) 82
dose-response relationship, drug (72) 72
antineoplastic combined chemotherapy protocols - adverse effects (68) 68
drug administration schedule (68) 68
school systems (68) 68
research (65) 65
colleges & universities (62) 62
breast neoplasms - drug therapy (61) 61
pharmacology & pharmacy (59) 59
antineoplastic agents - administration & dosage (57) 57
antineoplastic agents - adverse effects (56) 56
care and treatment (56) 56
education (56) 56
maximum tolerated dose (55) 55
paclitaxel (50) 50
community colleges (49) 49
county executives (49) 49
medicine & public health (49) 49
antineoplastic agents - therapeutic use (46) 46
tumors (46) 46
pharmacokinetics (44) 44
administrative law (43) 43
antineoplastic agents - pharmacokinetics (43) 43
local elections (42) 42
middle schools (42) 42
neoplasm staging (42) 42
breast neoplasms - pathology (41) 41
lung neoplasms - drug therapy (41) 41
pharmacology/toxicology (41) 41
breast cancer (39) 39
elementary schools (39) 39
paclitaxel - administration & dosage (39) 39
carboplatin (38) 38
drug therapy (38) 38
disease-free survival (37) 37
hematology, oncology and palliative medicine (37) 37
bevacizumab (36) 36
clinical trials (36) 36
deoxycytidine - analogs & derivatives (36) 36
school districts (36) 36
solid tumors (36) 36
docetaxel (35) 35
infusions, intravenous (35) 35
trial (34) 34
carboplatin - administration & dosage (33) 33
antineoplastic combined chemotherapy protocols - administration & dosage (32) 32
learning (32) 32
deoxycytidine - administration & dosage (31) 31
trastuzumab (31) 31
neoplasms - pathology (30) 30
therapy (30) 30
administration, oral (29) 29
cisplatin (29) 29
antibodies, monoclonal - administration & dosage (28) 28
dosage and administration (28) 28
neoplasm metastasis (28) 28
analysis (27) 27
antineoplastic agents (27) 27
patients (27) 27
survival rate (27) 27
antibodies, monoclonal, humanized (26) 26
carcinoma, non-small-cell lung - drug therapy (26) 26
cell lung-cancer (26) 26
college students (26) 26
gemcitabine (26) 26
awards & honors (25) 25
camptothecin - analogs & derivatives (25) 25
metastasis (25) 25
paclitaxel - adverse effects (25) 25
cancer research (24) 24
follow-up studies (24) 24
safety (23) 23
antibodies, monoclonal - adverse effects (22) 22
carcinoma (22) 22
combination (22) 22
multicenter (22) 22
neutropenia - chemically induced (22) 22
secondary school students (22) 22
survival (22) 22
antimitotic agents (21) 21
receptor, erbb-2 - metabolism (21) 21
toxicity (21) 21
area under curve (20) 20
deoxycytidine - adverse effects (20) 20
efficacy (20) 20
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (5) 5
Architecture Landscape (Shore + Moffat) - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Stacks (1) 1
Knox College (Caven) - Stacks (1) 1
Mathematical Sciences - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 42 - 51
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 14, pp. 2311 - 2319
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1133 - 1142
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 4, pp. 398 - 405
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2005, Volume 352, Issue 26, pp. 2696 - 2704
Journal Article